Latest Breaking News On - Purna pharmaceuticals - Page 1 : comparemela.com

Gynecology Collaboration, R&D, and Licensing Deals Trends

Gynecology Collaboration, R&D, and Licensing Deals Trends
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesMybiotics pharmaBiosyent pharmaMayne pharmaUlisse biomedValeo pharmaCocrystal pharmaPierre fabreEurofins lifecodexxMicrobix biosystemsAsieris meditechIndegene lifesystemsGenea biomedxXbrane bioscienceMillicent pharmaInserm transfert

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha

Miconazole domiphenJean luc vandebroekStijn van rompayHyloris pharmaceuticalsPurna pharmaceuticalsHyloris pharmaceuticals sa euronext brusselsPurna female healthcare announce positive resultsAcute vulvovaginal candidiasisDomiphen bromideEuronext brusselsMiconazole domiphen bromideVan rompayChief executive officerFemale healthcareLuc vandebroekLancet infectious diseases

Hyloris and Purna Female Healthcare Announce Positive

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms.

Jean luc vandebroekMiconazole domiphenStijn van rompayHyloris pharmaceuticals sa euronext brusselsPurna pharmaceuticalsHyloris pharmaceuticalsPurna female healthcare announce positive resultsAcute vulvovaginal candidiasisDomiphen bromideEuronext brusselsMiconazole domiphen bromideVan rompayChief executive officerFemale healthcareLuc vandebroekLancet infectious diseases

Hyloris And Purna Female Healthcare Announce Positive Results From Phase 2 Trial In Patients With Acute Vulvovaginal Candidiasis (VVC)

Hyloris And Purna Female Healthcare Announce Positive Results From Phase 2 Trial In Patients With Acute Vulvovaginal Candidiasis (VVC)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Jean luc vandebroekMiconazole domiphenStijn van rompayPurna pharmaceuticalsGlobal info researchHyloris pharmaceuticalsHyloris pharmaceuticals sa euronext brusselsPurna female healthcare announce positive resultsAcute vulvovaginal candidiasisDomiphen bromideEuronext brusselsMiconazole domiphen bromideVan rompayChief executive officerFemale healthcareLuc vandebroek

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with =4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan 14 commercial products expected by 2024 Conference call and Liège, Belgium - 9 March 2021 - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021. Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our knowhow and innovative technol

United statesHong kongUnited kingdomCzech republicRegion flamandeUnited arab emiratesAbuz abyNew zealandAmber fennellVan rompayKensington pharmaBiocapital europeOlivier declercqChris welshMarc foidartMarieke vermeersch